{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:37:22Z","timestamp":1790750242876,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.vaccine.2003.09.030","type":"journal-article","created":{"date-parts":[[2003,10,30]],"date-time":"2003-10-30T10:51:23Z","timestamp":1067511083000},"page":"1162-1171","source":"Crossref","is-referenced-by-count":66,"title":["A mixed Th1\/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB\/c mice"],"prefix":"10.1016","volume":"22","author":[{"given":"Tuhina","family":"Mazumdar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairul","family":"Anam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2003.09.030_BIB1","unstructured":"Pearson RD, Souza AQ, Jeronimo, SMB. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practise of infectious diseases V. Philadelphia: Churchill Livingstone; 2000; p. 2831\u201344."},{"issue":"2","key":"10.1016\/j.vaccine.2003.09.030_BIB2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.vaccine.2003.09.030_BIB3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.10.2.298","article-title":"Leishmania and human immunodeficiency virus coinfection: the first 10 years","volume":"10","author":"Alvar","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"issue":"7139","key":"10.1016\/j.vaccine.2003.09.030_BIB4","first-page":"1205","article-title":"Commentary: some good news for treatment of visceral leishmaniasis in Bihar","volume":"316","author":"Lockwood","year":"1998","journal-title":"Brit. Med. J."},{"issue":"11","key":"10.1016\/j.vaccine.2003.09.030_BIB5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Health"},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/infdis\/154.6.1003","article-title":"New perspectives on a subclinical form of visceral leishmaniasis","volume":"154","author":"Badaro","year":"1986","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.vaccine.2003.09.030_BIB7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.42.2.702-707.1983","article-title":"Cell mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis","volume":"42","author":"Haldar","year":"1983","journal-title":"Infect. Immun."},{"key":"10.1016\/j.vaccine.2003.09.030_BIB8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0952-7915(03)00069-4","article-title":"Vaccines for parasitic and bacterial diseases","volume":"15","author":"Reed","year":"2003","journal-title":"Curr. Opin. Immunol."},{"issue":"10","key":"10.1016\/j.vaccine.2003.09.030_BIB9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/374783","article-title":"Leishmania mexicana and Leishmania major: attenuation of wild type parasites and vaccination with attenuated lines","volume":"187","author":"Daneshvar","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2003.09.030_BIB10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0264-410X(01)00469-8","article-title":"Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony stimulating factors","volume":"20","author":"Follador","year":"2002","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2003.09.030_BIB11","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.146.8.2763","article-title":"Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis","volume":"146","author":"Kaye","year":"1991","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4269\/ajtmh.1983.32.51","article-title":"Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes","volume":"32","author":"Holbrook","year":"1983","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4269\/ajtmh.1985.34.1095","article-title":"Adoptive transfer of vaccine-induced resistance to Leishmania donovani","volume":"34","author":"Jarecki-Black","year":"1985","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.vaccine.2003.09.030_BIB14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe","year":"1990","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB15","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice from both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim","year":"1993","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.vaccine.2003.09.030_BIB16","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/IAI.69.8.4719-4725.2001","article-title":"Leishmania donovani p36 (LACK) DNA is highly immunogenic but not protective against experimental visceral leishmaniasis","volume":"69","author":"Melby","year":"2001","journal-title":"Infect. Immun."},{"issue":"9-10","key":"10.1016\/j.vaccine.2003.09.030_BIB17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0264-410X(00)00339-X","article-title":"A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)","volume":"19","author":"da Silva","year":"2000","journal-title":"Vaccine"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2003.09.030_BIB18","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2003.09.030_BIB19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0952-7915(98)80121-0","article-title":"Regulation of protective immunity against Leishmania major in mice","volume":"10","author":"Louis","year":"1998","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.vaccine.2003.09.030_BIB20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/IAI.62.3.1058-1063.1994","article-title":"Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis","volume":"62","author":"Miralles","year":"1994","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB21","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","article-title":"Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis","volume":"76","author":"Carvalho","year":"1985","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.4049\/jimmunol.148.6.1858","article-title":"Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity","volume":"148","author":"Murray","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.09.030_BIB23","first-page":"S91","article-title":"Cytotoxic T lymphocytes induced by liposomal antigens:mechanism of immunological presentation","volume":"10","author":"Alving","year":"1994","journal-title":"AIDS Res. Hum. Retrovirus"},{"issue":"7","key":"10.1016\/j.vaccine.2003.09.030_BIB24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0167-7799(98)01220-7","article-title":"Novel applications of liposomes","volume":"16","author":"Lasic","year":"1998","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.vaccine.2003.09.030_BIB25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0167-5699(90)90034-7","article-title":"Immunological adjuvants: a role for liposomes","volume":"11","author":"Gregoriadis","year":"1990","journal-title":"Immunol. Today"},{"issue":"11","key":"10.1016\/j.vaccine.2003.09.030_BIB26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0264-410X(97)00015-7","article-title":"Immunogenecity and protectivity of a new liposomal hepatitis A vaccine","volume":"15","author":"Ambrosch","year":"1997","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB27","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/IAI.66.6.2859-2865.1998","article-title":"Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen","volume":"66","author":"Richards","year":"1998","journal-title":"Infect. Immun."},{"issue":"8\u20139","key":"10.1016\/j.vaccine.2003.09.030_BIB28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0161-5890(97)00090-4","article-title":"Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen","volume":"34","author":"Fernandes","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.vaccine.2003.09.030_BIB29","unstructured":"Gregoriadis G. Liposome technology, vol. I, 2nd ed. Boca Raton, FL: CRC Press; 1993."},{"issue":"8","key":"10.1016\/j.vaccine.2003.09.030_BIB30","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.4049\/jimmunol.161.8.4000","article-title":"Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen","volume":"161","author":"Brewer","year":"1998","journal-title":"J. Immunol."},{"issue":"1-2","key":"10.1016\/j.vaccine.2003.09.030_BIB31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(99)00097-8","article-title":"Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble protein","volume":"61","author":"Nakanishi","year":"1999","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.vaccine.2003.09.030_BIB32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/S0100-879X1999000200006","article-title":"Liposomes from biophysics to the design of peptide vaccines","volume":"32","author":"Frezard","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"10","key":"10.1016\/j.vaccine.2003.09.030_BIB33","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V96.10.3505","article-title":"Presentation of proteins encapsulated liposomes by dendritic cells initiates CD8+ T-cell responses in vivo","volume":"96","author":"Ignatius","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.vaccine.2003.09.030_BIB34","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1128\/IAI.70.12.6697-6706.2002","article-title":"Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB\/c mice","volume":"70","author":"Afrin","year":"2002","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.vaccine.2003.09.030_BIB35","first-page":"507","article-title":"Enhancement of immunogenecity of tumour virus antigen by liposomes: the effect of lipid composition","volume":"58","author":"Bakouche","year":"1986","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.vaccine.2003.09.030_BIB36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-2478(89)90086-2","article-title":"Immunoadjuvant action of liposomes: comparison with other adjuvants","volume":"20","author":"Gregoriadis","year":"1989","journal-title":"Immunol. Lett."},{"issue":"12","key":"10.1016\/j.vaccine.2003.09.030_BIB37","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.4049\/jimmunol.142.12.4441","article-title":"Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen\/liposomes","volume":"142","author":"Kahl","year":"1989","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB38","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/IAI.65.6.2371-2377.1997","article-title":"Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes","volume":"65","author":"Afrin","year":"1997","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.vaccine.2003.09.030_BIB40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1550-7408.1958.tb02565.x","article-title":"An 8-day method for screening compounds against Leishmania donovani in the golden hamster","volume":"5","author":"Stauber","year":"1958","journal-title":"J. Protozool."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1645\/0022-3395(2001)087[0188:LAOSBL]2.0.CO;2","article-title":"Leishmanicidal activity of stearylamine-bearing liposomes in vitro","volume":"87","author":"Afrin","year":"2001","journal-title":"J. Parasitol."},{"issue":"3","key":"10.1016\/j.vaccine.2003.09.030_BIB42","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/1521-4141(200003)30:3<834::AID-IMMU834>3.0.CO;2-9","article-title":"IL-12 gene deficient C57B2\/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology","volume":"30","author":"Satoskar","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.vaccine.2003.09.030_BIB43","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.4049\/jimmunol.141.7.2407","article-title":"Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production","volume":"141","author":"Ding","year":"1988","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.vaccine.2003.09.030_BIB44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2307\/3284581","article-title":"Isotype profiles of Leishmania donovani infected BALB\/c mice: preferential stimulation of IgG2a\/b by liposome-associated promastigote antigens","volume":"84","author":"Afrin","year":"1998","journal-title":"J. Parasitol."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2307\/3284319","article-title":"Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes","volume":"83","author":"Ali","year":"1997","journal-title":"J. Parasitol."},{"issue":"12","key":"10.1016\/j.vaccine.2003.09.030_BIB46","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"Stager","year":"2000","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/IAI.66.1.18-27.1998","article-title":"Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani","volume":"66","author":"Melby","year":"1998","journal-title":"Infect. Immun."},{"issue":"5","key":"10.1016\/j.vaccine.2003.09.030_BIB48","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/515265","article-title":"Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up","volume":"177","author":"Armijos","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"5144","key":"10.1016\/j.vaccine.2003.09.030_BIB49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.vaccine.2003.09.030_BIB50","first-page":"2077","article-title":"Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis","volume":"16","author":"Sj\u00f6lander","year":"1998","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.vaccine.2003.09.030_BIB51","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/516482","article-title":"Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis","volume":"175","author":"Murray","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.vaccine.2003.09.030_BIB52","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.4049\/jimmunol.143.12.4244","article-title":"Experimental visceral leishmaniasis: role of endogenous IFN-\u03b3 in host defense and tissue granulomatous response","volume":"143","author":"Squires","year":"1989","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.vaccine.2003.09.030_BIB53","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1084\/jem.185.7.1231","article-title":"Intracellular antimicrobial activity in the absence of interferon-\u03b3: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-\u03b3 gene disrupted mice","volume":"185","author":"Taylor","year":"1997","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.vaccine.2003.09.030_BIB54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1084\/jem.189.4.741","article-title":"Macrophage microbicidal mechanisims in vivo: reactive nitrogen versus oxygen intermediates in killing of intracellular visceral Leishmania donovani","volume":"189","author":"Murray","year":"1999","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.vaccine.2003.09.030_BIB55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/IAI.69.1.245-251.2001","article-title":"Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection","volume":"69","author":"Gicheru","year":"2001","journal-title":"Infect. Immun."},{"issue":"20","key":"10.1016\/j.vaccine.2003.09.030_BIB56","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0264-410X(98)00075-9","article-title":"Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection","volume":"16","author":"Sj\u00f6lander","year":"1998","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2003.09.030_BIB57","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/IAI.63.12.4894-4899.1995","article-title":"Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection","volume":"63","author":"Satoskar","year":"1995","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.vaccine.2003.09.030_BIB58","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.4049\/jimmunol.166.3.1921","article-title":"Protective immunity against the protozoan Leishmania chagasi is induced by subclinical infection with virulent but not avirulent organisms","volume":"166","author":"Streit","year":"2001","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2003.09.030_BIB59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infection","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2003.09.030_BIB60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-3083.2001.00900.x","article-title":"CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13","volume":"53","author":"Bullens","year":"2001","journal-title":"Scand. J. Immunol."},{"issue":"11","key":"10.1016\/j.vaccine.2003.09.030_BIB61","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni725","article-title":"IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB\/c mice","volume":"2","author":"Biedermann","year":"2001","journal-title":"Nature Immunol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03007059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X03007059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:17:18Z","timestamp":1682590638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X03007059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":61,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0264410X03007059"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.09.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}